Sorrento Therapeutics, Inc. Stock
Stocks
SRNE
US83587F2020
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
OTC Markets
28/08/2026
|
5-day change | 1st Jan Change | ||
| 0.000500 USD | -.--% |
|
-37.50% | -80.77% |
| 03-18 | Semnur Pharmaceuticals, Inc. Announces CEO Changes, Effective March 13, 2026 | CI |
| 03-18 | Semnur Pharmaceuticals, Inc. Announces Management Changes | CI |
| Market Cap | 67.15M 57.81M 54.29M 49.55M 93.09M 6.39B 93.76M 643M 250M 3.24B 252M 247M 10.73B | P/E 2021 |
-3.2x | P/E 2022 | -0.65x |
|---|---|---|---|---|---|
| Enterprise Value | 152M 131M 123M 112M 210M 14.43B 212M 1.45B 565M 7.32B 569M 557M 24.23B | EV / Sales 2021 |
29.1x | EV / Sales 2022 | 7.89x |
| Free-Float |
98.65% | Yield 2021 * |
-
| Yield 2022 | - |
| 1 week | -37.50% | ||
| 6 months | -76.19% | ||
| Current year | -80.77% |
| 1 week | 0 |  | 0 |
| 1 month | 0 | | 0.01 |
| Current year | 0 | | 0.01 |
| 1 year | 0 | | 0.1 |
| 3 years | 0 | | 0.25 |
| 5 years | 0 | | 9.31 |
| 10 years | 0 | | 19.39 |
| Manager | Title | Age | Since |
|---|---|---|---|
Henry Ji
CEO | Chief Executive Officer | 61 | 01/04/2011 |
Scott Schaus
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/2022 |
John Waldheim
LAW | General Counsel | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Henry Ji
CHM | Chairman | 61 | 01/08/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -37.50% | -91.67% | -99.63% | 272K | |
| -1.66% | -4.96% | +49.84% | +88.43% | 68.13B | |
| -2.19% | +1.32% | +44.54% | +88.38% | 63.6B | |
| +2.21% | +2.72% | +38.74% | +13.07% | 25.57B | |
| +2.77% | -1.74% | -16.16% | +456.51% | 26.6B | |
| -0.46% | -9.94% | +0.98% | -15.98% | 25.52B | |
| -9.71% | -0.36% | +245.87% | +377.68% | 18.23B | |
| -1.58% | +0.47% | +29.35% | -19.62% | 19.69B | |
| -1.57% | -6.12% | +1.03% | +541.83% | 15.16B | |
| +0.35% | +0.16% | +46.96% | +144.04% | 13.54B | |
| Average | -1.15% | -6.19% | +34.95% | +157.47% | 27.6B | |
| Weighted average by Cap. | -1.29% | -2.34% | +45.37% | +146.28% |
| 2021 | 2022 | |
|---|---|---|
| Net sales | 52.9M 45.55M 42.77M 39.04M 73.34M 5.03B 73.87M 507M 197M 2.55B 199M 194M 8.45B | 62.84M 54.1M 50.8M 46.37M 87.12M 5.98B 87.74M 602M 234M 3.03B 236M 231M 10.04B |
| Net income | -428M -369M -346M -316M -594M -40.75B -598M -4.1B -1.6B -20.67B -1.61B -1.57B -68.43B | -573M -493M -463M -423M -794M -54.51B -800M -5.49B -2.14B -27.64B -2.15B -2.1B -91.52B |
| Net Debt | 111M 95.31M 89.49M 81.69M 153M 10.53B 155M 1.06B 413M 5.34B 416M 407M 17.68B | 84.53M 72.78M 68.34M 62.38M 117M 8.04B 118M 810M 315M 4.08B 317M 310M 13.5B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/08/26 | $0.000500 | -.--% | 26,838 |
| 28/08/26 | $0.000500 | -.--% | 26,750 |
| 27/08/26 | $0.000500 | -44.44% | 103,292 |
| 26/08/26 | $0.000900 | +28.57% | 135,982 |
| 25/08/26 | $0.000700 | -12.50% | 332,415 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- SRNE Stock
Select your edition
All financial news and data tailored to specific country editions
